FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.
What happened
FDA reviewed DirectMeds' website in August 2025 and found it offered compounded semaglutide and tirzepatide. FDA said website claims—such as saying the compounded products use the same active ingredient as brand-name drugs—were false or misleading because compounded drugs are not FDA-approved. No inspection was conducted.
What FDA found
Website claims for compounded semaglutide and tirzepatide are false or misleading because they imply the products are the same as FDA-approved drugs when compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The company introduced or delivered for introduction into interstate commerce drugs that FDA says are misbranded.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receipt in interstate commerce of misbranded drugs, and delivery or offered delivery of them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells DirectMeds to take immediate action, including ceasing the misleading language, and to respond in writing within 15 working days of receipt to CDER's Office of Compounding Quality and Compliance with steps taken, prevention plans, and supporting documents. If unable to complete the matter, it must explain the delay and give a completion time.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies that supply online sellers
- marketing and compliance teams for online drug sellers
This is a summary. Read the original letter on fda.gov.